Clinical Trial Detail

NCT ID NCT02974621
Title Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

glioblastoma multiforme

Therapies

Bevacizumab

Cediranib + Olaparib

Age Groups: adult senior

No variant requirements are available.